PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35217990-0	2022	Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer.	Metformin	86-95	dedicator of cytokinesis 1	Homo sapiens	65-70	
35217990-5	2022	Mechanistically, metformin promotes DOCK1 phosphorylation, which activates RAC1 to facilitate cell survival, leading to metformin resistance.	Metformin	17-26	dedicator of cytokinesis 1	Homo sapiens	36-41	
35217990-5	2022	Mechanistically, metformin promotes DOCK1 phosphorylation, which activates RAC1 to facilitate cell survival, leading to metformin resistance.	Metformin	120-129	dedicator of cytokinesis 1	Homo sapiens	36-41	
35217990-6	2022	The DOCK1-selective inhibitor, TBOPP, potentiates anti-tumor activity by metformin in vitro in liver cancer cell lines and patient-derived HCC organoids, and in vivo in xenografted liver cancer cells and immunocompetent mouse liver cancer models.	Metformin	73-82	dedicator of cytokinesis 1	Homo sapiens	4-9	
35217990-7	2022	Notably, metformin improves overall survival of HCC patients with low DOCK1 levels but not among patients with high DOCK1 expression.	Metformin	9-18	dedicator of cytokinesis 1	Homo sapiens	70-75	
35217990-8	2022	This study shows that metformin effectiveness depends on DOCK1 levels and that combining metformin with DOCK1 inhibition may provide a promising personalized therapeutic strategy for metformin-resistant HCC patients.	Metformin	22-31	dedicator of cytokinesis 1	Homo sapiens	57-62	
35217990-8	2022	This study shows that metformin effectiveness depends on DOCK1 levels and that combining metformin with DOCK1 inhibition may provide a promising personalized therapeutic strategy for metformin-resistant HCC patients.	Metformin	22-31	dedicator of cytokinesis 1	Homo sapiens	104-109	
35217990-8	2022	This study shows that metformin effectiveness depends on DOCK1 levels and that combining metformin with DOCK1 inhibition may provide a promising personalized therapeutic strategy for metformin-resistant HCC patients.	Metformin	89-98	dedicator of cytokinesis 1	Homo sapiens	57-62	
35217990-8	2022	This study shows that metformin effectiveness depends on DOCK1 levels and that combining metformin with DOCK1 inhibition may provide a promising personalized therapeutic strategy for metformin-resistant HCC patients.	Metformin	183-192	dedicator of cytokinesis 1	Homo sapiens	104-109	
35217990-4	2022	Here, through a genome-wide CRISPR-Cas9-based knockout screen, we find that DOCK1 levels determine the anti-tumor effects of metformin and that DOCK1 is a synthetic lethal target of metformin in HCC.	Metformin	125-134	dedicator of cytokinesis 1	Homo sapiens	76-81	
35217990-4	2022	Here, through a genome-wide CRISPR-Cas9-based knockout screen, we find that DOCK1 levels determine the anti-tumor effects of metformin and that DOCK1 is a synthetic lethal target of metformin in HCC.	Metformin	182-191	dedicator of cytokinesis 1	Homo sapiens	144-149